The Broad Institute’s Genomics Platform brings together over 20 years of experience in the management of advanced technologies, applications development, data management, and high-throughput processes relating to sample handling, genotyping, gene expression, and genome sequencing. Through the close coordination and integration of three former institute platforms — the Genome Sequencing Platform, the Biological Samples Platform, and the Genetic Analysis Platform — the newly created Genomics Platform offers an unprecedented level of access to and capabilities for leveraging genomic technologies, enabling the Broad to address the ambitious biological questions it aims to pursue.
This dynamic, integrated platform provides comprehensive genomic services to the Broad scientific community and continues to push the boundaries of the genomic frontier through the application of operational excellence, advanced process design, data analysis and visualization, and technology development capabilities. The Genomics Platform explores, validates, optimizes, and implements new technologies, methods and analysis tools to make them widely available to meet the needs of the Broad community.
This new group is designed to enable cutting-edge science by increasing outreach, collaboration and communication while simultaneously reducing costs and cycle times. Incorporating not just three prominent laboratory groups, the new platform also integrates notable informatics, data analysis, and project management skills across projects and processes to create a streamlined experience for its collaborators.
Clinical Research Sequencing Platform
The Broad Clinical Research Sequencing Platform is a clinical laboratory licensed by the State of Massachusetts (License No 3306) and registered with the Centers for Medicare and Medicaid Services to provide testing under the CLIA regulations.
The Clinical Research Sequencing Platform (CRSP) was created to further the Broad Institute mission of creating and making available tools for genomic medicine, and applying them to human diseases.
CRSP is the route for physicians and physician-researchers to access high quality molecular tests such as Whole Exome Sequencing offered by the Broad Institute in a CLIA setting.
The CRSP team is working on an array of additional assays and analytical tools to be validated and released in coming months. These include Firehose analysis modules including MuTect3 and InDelocator for the analysis of tumor-normal pairs from cancer patients. Also coming soon is a Broad-designed, comprehensive cancer targeted panel.
If you would like to initiate a project or get more information, please use the Genomics Platform inquiry form to contact us. A member of the team will get in touch with you directly to discuss how to move forward with your project.